Despite diverse types of VEGF pathway inhibitors which contribute to ameliorating the survival of most cancer patients, some patients gain little or no beneficial effects from them due to the resistance to these anti-VEGF inhibitors (Itatani et al., 2018). The gene discussed is VEGFA; the disease is cancer.